Search clinical trials for: PD-L1 gastric cancer
Total 92828 results
-
Wuxi People's HospitalRecruitingCancer | PD-L1 Gene MutationChina
-
China Meitan General HospitalMarino Biotechnology Co., Ltd.UnknownRecurrent PD-L1+ Malignant Tumors | Metastatic PD-L1+ Malignant TumorsChina
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsSpain, Korea, Republic of, China, Taiwan, Turkey, Greece, United States, Croatia, Serbia, Canada, Mexico, Cyprus, Georgia
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Inge Marie SvaneCompletedPolycythemia Vera | Essential ThrombocythemiaDenmark
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Shanghai Zhongshan HospitalRecruiting
-
Tatarstan Cancer CenterUnknownHereditary Breast CancerRussian Federation
-
ImmunityBio, Inc.Active, not recruitingSolid Tumor | Metastatic Cancer | Locally Advanced Solid TumorUnited States
-
Zhongnan HospitalRecruiting
-
Medical University of ViennaUnknownNon Small Cell Lung CancerAustria
-
Baodong QinUnknown
-
Hoffmann-La RocheCompletedCarcinoma, Non-Small-Cell Lung | Carcinoma, Small CellUnited Kingdom, Czechia, Germany, Poland, Spain, Switzerland
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
University Hospital, AngersCompletedCancer | Sleep Apnea Syndromes, ObstructiveFrance
-
Binhui Biopharmaceutical Co., Ltd.Recruiting
-
ImmunityBio, Inc.Active, not recruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair DeficiencyUnited States
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
-
Thomas MarronRecruiting
-
Lars Møller PedersenCompletedFollicular LymphomaDenmark
-
Shanghai Zhongshan HospitalRecruitingCholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4China
-
Centre Leon BerardNETRIS PharmaRecruitingAdvanced Solid Tumors | Metastatic Solid TumorsFrance
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Sichuan UniversityRecruitingMalignant Ascites | Malignant Peritoneal Effusion | Serous Cavity MetastatisesChina
-
Sichuan UniversityRecruitingPleural Effusion, Malignant | Peritoneal Carcinoma MetastaticChina
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Lene Meldgaard KnudsenIO BiotechTerminatedSmoldering Multiple MyelomaDenmark
-
Peking Union Medical College HospitalRecruitingHepatocellular CarcinomaChina
-
Shanghai Henlius BiotechRecruitingAdvanced Solid TumorChina
-
Lene Meldgaard KnudsenCompleted
-
Jiangsu Alphamab Biopharmaceuticals Co., LtdSunshine Lake Pharma Co., Ltd.Terminated
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingCervical Cancer | Advanced Solid TumorChina
-
The Second Hospital of Nanjing Medical UniversityUnknownPrimary Hepatocellular Carcinoma
-
Herlev and Gentofte HospitalUniversity of CopenhagenCompleted
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Maastricht Radiation OncologyCompletedProstate Cancer | PD-L1Netherlands
-
Shanghai Zhongshan HospitalRecruitingOesophageal Squamous Cell CarcinomaChina
-
Naestved HospitalRecruitingNon-small Cell Lung Cancer | Malignant Pleural EffusionDenmark
-
Kidney Cancer Research BureauRecruitingMetastatic Gastric Cancer | FGFR2 Amplification | PD-L1 Gene AmplificationUnited States
-
Sichuan UniversityNot yet recruitingAdvanced Solid TumorChina
-
Sarah GoldbergMirati Therapeutics Inc.TerminatedLung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | SitravatinibUnited States
-
Lei LiRecruitingMicrosatellite Instability | Recurrent Cervical Cancer | PD-L1 | Nucleotide Variant | Copy Number Variation | Insertion-deletion Variation | Genomic Structural Variation | Total Mutation Burden | PD-1China
-
Poitiers University HospitalActive, not recruitingNon Small Cell Lung Cancer | Gene Mutation-Related Cancer | PD-L1 | PET/CTFrance
-
Merck Sharp & Dohme LLCActive, not recruitingCarcinoma, Non-squamous Non-small-cell LungPoland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
-
Merck Sharp & Dohme LLCRecruitingSolid Tumors | Hematologic MalignanciesUnited States, Poland, Brazil, Ukraine, Argentina, Australia, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic... and more